Vericel Corp

More Details of Vericel Corp Company

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.

Company Info

Ticker SymbolVCEL

Company nameVericel Corp

IPO dateFeb 04, 1997

Founded at1989

CEOMr. Dominick C. Colangelo

Number of employees357

Security typeOrdinary Share

Fiscal year-endFeb 04

Address64 Sidney St

CityCAMBRIDGE

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code02139

Phone17349305555

Websitehttps://vcel.com/

Ticker SymbolVCEL

IPO dateFeb 04, 1997

Founded at1989

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Dominick C. Colangelo

President, Chief Executive Officer, Director

260.28K

--

Dr. Jonathan Mark Hopper

Chief Medical Officer

66.21K

--

Mr. Alan L. Rubino

Independent Director

45.99K

+7.48%

Dr. Paul K. Wotton, Ph.D.

Independent Director

30.60K

+11.68%

Dr. Robert L. Zerbe, M.D.

Independent Chairman of the Board

29.80K

+12.03%

Mr. Michael Halpin

Chief Operating Officer

15.63K

+2.77%

Mr. Kevin F. Mclaughlin

Independent Director

15.10K

--

Ms. Lisa Wright

Independent Director

12.65K

+33.86%

Mr. Sean C. Flynn

Chief Legal Officer

971.00

+105.29%

Ms. Heidi M. Hagen

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Dominick C. Colangelo

President, Chief Executive Officer, Director

260.28K

--

Dr. Jonathan Mark Hopper

Chief Medical Officer

66.21K

--

Mr. Alan L. Rubino

Independent Director

45.99K

+7.48%

Dr. Paul K. Wotton, Ph.D.

Independent Director

30.60K

+11.68%

Dr. Robert L. Zerbe, M.D.

Independent Chairman of the Board

29.80K

+12.03%

Mr. Michael Halpin

Chief Operating Officer

15.63K

+2.77%

Revenue Breakdown

Currency: USDUpdated: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

MACI

46.30M

88.02%

Epicel

4.96M

9.44%

NexoBrid

1.34M

2.54%

By RegionUSD

Name

Revenue

Proportion

United States

52.60M

100.00%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

MACI

46.30M

88.02%

Epicel

4.96M

9.44%

NexoBrid

1.34M

2.54%

Shareholding Stats

Updated: Sun, Apr 20

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

14.43%

The Vanguard Group, Inc.

6.92%

Brown Capital Management, LLC

5.72%

State Street Global Advisors (US)

4.84%

Fidelity Management & Research Company LLC

4.35%

Other

63.74%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

14.43%

The Vanguard Group, Inc.

6.92%

Brown Capital Management, LLC

5.72%

State Street Global Advisors (US)

4.84%

Fidelity Management & Research Company LLC

4.35%

Other

63.74%

Shareholder Types

Shareholders

Proportion

Investment Advisor

54.26%

Investment Advisor/Hedge Fund

45.86%

Pension Fund

2.90%

Research Firm

2.86%

Hedge Fund

1.09%

Individual Investor

1.06%

Bank and Trust

0.92%

Insurance Company

0.10%

Sovereign Wealth Fund

0.06%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

533

54.94M

109.13%

-1.35M

2025Q1

559

55.34M

109.94%

-1.25M

2024Q4

543

54.07M

108.22%

-1.11M

2024Q3

519

52.64M

107.39%

-2.94M

2024Q2

509

52.53M

108.12%

-3.27M

2024Q1

499

52.78M

109.13%

-3.92M

2023Q4

473

53.52M

112.14%

-4.39M

2023Q3

463

53.25M

111.77%

-4.17M

2023Q2

465

51.63M

108.55%

-6.73M

2023Q1

480

52.04M

109.66%

-6.96M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

7.26M

14.43%

-231.46K

-3.09%

Mar 31, 2025

The Vanguard Group, Inc.

3.48M

6.92%

+6.84K

+0.20%

Mar 31, 2025

Brown Capital Management, LLC

2.88M

5.72%

-353.58K

-10.93%

Mar 31, 2025

State Street Global Advisors (US)

2.44M

4.84%

+32.41K

+1.35%

Mar 31, 2025

Fidelity Management & Research Company LLC

2.19M

4.35%

+146.00K

+7.15%

Mar 31, 2025

Conestoga Capital Advisors, LLC

2.06M

4.1%

-7.83K

-0.38%

Mar 31, 2025

Invesco Advisers, Inc.

1.98M

3.94%

+60.96K

+3.17%

Mar 31, 2025

Congress Asset Management Company, LLP

1.48M

2.93%

+22.58K

+1.55%

Mar 31, 2025

GW&K Investment Management, LLC

1.43M

2.85%

+158.47K

+12.44%

Mar 31, 2025

Geneva Capital Management LLC

1.37M

2.71%

+265.96K

+24.18%

Mar 31, 2025

Related ETFs

Updated: Sun, Jul 6

Name

Proportion

ALPS Medical Breakthroughs ETF

1.8%

Invesco S&P SmallCap Health Care ETF

1.45%

AAM Sawgrass US Small Cap Quality Growth ETF

1.2%

SPDR S&P Biotech ETF

0.53%

Invesco S&P SmallCap 600 Pure Growth ETF

0.45%

First Trust NASDAQ Pharmaceuticals ETF

0.45%

OneAscent Small Cap Core ETF

0.34%

SPDR S&P 600 Small Cap Growth ETF

0.32%

WisdomTree US SmallCap Quality Growth Fund

0.32%

Vanguard S&P Small-Cap 600 Growth Index Fund

0.32%

ALPS Medical Breakthroughs ETF

Proportion1.8%

Invesco S&P SmallCap Health Care ETF

Proportion1.45%

AAM Sawgrass US Small Cap Quality Growth ETF

Proportion1.2%

SPDR S&P Biotech ETF

Proportion0.53%

Invesco S&P SmallCap 600 Pure Growth ETF

Proportion0.45%

First Trust NASDAQ Pharmaceuticals ETF

Proportion0.45%

OneAscent Small Cap Core ETF

Proportion0.34%

SPDR S&P 600 Small Cap Growth ETF

Proportion0.32%

WisdomTree US SmallCap Quality Growth Fund

Proportion0.32%

Vanguard S&P Small-Cap 600 Growth Index Fund

Proportion0.32%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

36.260USD

Vericel Corp

36.260

Overview

Company

Financials